Mycobacterium tuberculosis is ready to colonize, persist, and massively replicate in host cells, resembling phagocytes and epithelial cells. The intracellular stage of the micro organism is important to the event of tuberculosis pathogenesis. The detailed mechanisms of intracellular trafficking of the bacillus will not be totally understood and require additional investigations.
Therefore, rising the information of this course of will assist to develop therapeutic instruments that may decrease the burden of tuberculosis. M. tuberculosis is genetically tractable and tolerates the expression of heterologous fluorescent proteins. Thus, the intracellular distribution of the micro organism expressing fluorescent tracers will be simply outlined utilizing confocal microscopy.
Advances in imaging methods and images-based evaluation permit the speedy quantification of organic objects in advanced environments. In this chapter, we detailed high-content / high-throughput imaging strategies to trace the bacillus inside host cell settings.
Oligo-Mediated Recombineering and its Use for Making SNPs, Knockouts, Insertions, and Fusions in Mycobacterium tuberculosis
Phage recombination techniques have been instrumental within the growth of gene modification applied sciences for bacterial pathogens. In specific, the Che9 phage RecET system has been used efficiently for over 10 years for making gene knockouts and fusions in Mycobacterium tuberculosis. This “recombineering” expertise sometimes makes use of linear dsDNA substrates that comprise a drug-resistance marker flanked by (as much as) 500 base pairs of DNA homologous to the goal website.
Less usually employed in mycobacterial recombineering is the use of oligonucleotides, which require solely the motion of the RecT annealase to align oligos to ssDNA areas of the replication fork, for subsequent incorporation into the chromosome. Despite the upper frequency of such occasions relative to dsDNA-promoted recombineering, oligo-mediated adjustments typically endure from the drawback of not being selectable, thus making them more durable to isolate.
This chapter discusses steps and methodologies that improve the frequencies of discovering oligo-mediated occasions, together with the switch of single nucleotide polymorphisms (SNPs) to mycobacterial chromosomes, and the use of oligos along side the mycobacterial phage Bxb1 site-specific recombination system for the straightforward era of knockouts, insertion, and fusions, in a protocol generally known as ORBIT.
Reduced thyroxine manufacturing in younger family contacts of tuberculosis sufferers will increase energetic tuberculosis illness danger
In the present examine, we adopted 839 family contacts (HHCs) of tuberculosis (TB) sufferers for two years and recognized the elements that enhanced the event of TB. Fourteen of the 17 HHCs who progressed to TB had been within the 15- to 30-year-old age group. At baseline (the “0” time level, when all of the people had been wholesome), the focus of the thyroid hormone thyroxine (T4) was decrease, and there have been elevated numbers of Tregs in PBMCs of TB progressors.
At baseline, PBMCs from TB progressors stimulated with early secretory antigenic goal 6 (ESAT-6) and 10 kDa tradition filtrate antigen (CFP-10) produced much less IL-1α. Thyroid hormones inhibited Mycobacterium tuberculosis (Mtb) progress in macrophages in an IL-1α-dependent method. Mtb-infected Thra1PV/+ (mutant thyroid hormone receptor) mice had elevated mortality and decreased IL-1α manufacturing. Our findings recommend that younger HHCs who exhibit decreased manufacturing of thyroid hormones are at excessive danger of creating energetic TB illness.
Primary Eustachian Tube Tuberculosis
Nasopharyngeal tuberculosis is a uncommon incidence, and primarily entails the proximal half of the Eustachian tube. Mechanical obstruction of the Eustachian tube will have an effect on the stress discrepancy between the center ear and the exterior ambiance, resulting in aural fullness, unilateral listening to disturbance, and otitis media.
These situations will be ignored or mistakenly identified as ear pathology. We report a case of unilateral listening to loss and tinnitus in a 31-year-old wholesome lady that was later confirmed to be tuberculosis of the Eustachian tube. In circumstances with indicators suggesting a excessive index of suspicion, an intensive examination of the top and neck areas is very crucial. Once it has been identified, Eustachian tuberculosis will be efficiently handled with anti-tuberculosis drugs.
Drug Sensitivity Testing of Mycobacterium tuberculosis Growing in a Hollow Fiber Bioreactor
Hollow fiber techniques (HFSs) have been broadly utilized to check pharmacokinetic-pharmacodynamic (PK-PD) relationships in antibiotic analysis and growth. The system contains a bundle of high-density hole capillary fibers that conduct a movement of medium with or with out drug and an extra-capillary area (ECS) inoculated with the pathogen of curiosity.
The semipermeable membrane of the hole fibers permits for speedy change of small molecule medication and solutes, whereas the pathogen is restricted to the ECS. The distinctive properties of the HFS are (1) the flexibility to simulate any PK profile inside the fibers and ECS, together with plasma or site-of-disease PK profiles, (2) the flexibility to concurrently enter a number of medication with totally different half-lives, (3) the flexibility to control progress situations resembling medium composition, carbon supply, and pH, and (4) the flexibility to pattern in each compartments to be able to monitor drug concentrations and bacterial progress kinetics over time.
The system is especially suited to Mycobacterium tuberculosis analysis in a biosafety stage 3 (BSL3) atmosphere since pathogenic micro organism are sequestered in an remoted compartment. The HFS was certified by the European Medicines Agency for antituberculosis drug growth in 2015. Here, we describe the usual procedures used to check the expansion kinetics of M. tuberculosis within the HFS and the killing impact of first-line antituberculous medication utilized underneath simulated human PK situations. This animal-sparing and economical instrument will be utilized to optimize dosing schedules that reduce emergence of resistance and to prioritize drug regimens that speed up sterilization.
Exploiting Fluorescent Proteins to Understand Mycobacterium tuberculosis Biology
The utility of fluorescent proteins in bacterial analysis has lengthy been appreciated, with intensive use within the Mycobacterium tuberculosis subject. In more moderen years, a brand new era of fluorescent instruments has been developed to be used in M. tuberculosis analysis. These new fluorescent reporters exploit the immense genetic and transcriptional information now accessible, and allow the use of the micro organism as direct reporters of the native atmosphere throughout an infection, in addition to present perception into bacterial replication standing in situ.
Brucella Abortus Antigen |
|||
| NAT41599-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
|
Description: Brucella abortus lysate, produced by fermentation. |
|||
Candida Albicans Antigen |
|||
| NAT41601-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Candida albicans is grown on solid medium, washed, disrupted and subjected to an extraction process. The antigen consists of cytoplasmic and cell wall components. |
|||
Candida Albicans Antigen |
|||
| NAT41601-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
|
Description: Candida albicans is grown on solid medium, washed, disrupted and subjected to an extraction process. The antigen consists of cytoplasmic and cell wall components. |
|||
Canine Parvovirus Antigen |
|||
| NAT41594-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Canine Parvovirus, produced in CRFK cells. |
|||
Canine Coronavirus Antigen |
|||
| NAT41590-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Canine Coronavirus produced in A-72 cells. |
|||
Feline Calicivirus Antigen |
|||
| NAT41595-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Feline Calicivirus produced in FC 3TG cells. |
|||
Helicobacter Pylori Antigen |
|||
| NAT41603-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Bacteria are cultured on solid medium, harvested, washed and solubilised. The antigen is partially purified by detergent extraction and centrifugation. |
|||
Helicobacter Pylori Antigen |
|||
| NAT41603-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
|
Description: Bacteria are cultured on solid medium, harvested, washed and solubilised. The antigen is partially purified by detergent extraction and centrifugation. |
|||
Campylobacter Jejuni Antigen |
|||
| NAT41600-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Campylobacter jejuni is cultured on solid medium. This antigen is a partially purified detergent extract of the membrane fraction. The main component is an outer membrane protein, approximately 45 kDa in SDS-PAGE. |
|||
Campylobacter Jejuni Antigen |
|||
| NAT41600-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
|
Description: Campylobacter jejuni is cultured on solid medium. This antigen is a partially purified detergent extract of the membrane fraction. The main component is an outer membrane protein, approximately 45 kDa in SDS-PAGE. |
|||
mycobacterium tuberculosis Antigen 85A Recombinant Protein |
|||
| PROTP9WQP3 | BosterBio | 10ug | EUR 265 |
|
Description: mycobacterium tuberculosis Antigen 85A Recombinant Protein expressed in Baculovirus with His-tag. Sequence domain: 44-338aa. Application(s): SDS-PAGE. Endotoxin: < 1 EU per 1ug of protein (determined by LAL method). |
|||
Chlamydia Trachomatis Antigen |
|||
| CT022-1000 | The Native Antigen Company | 1.0 | EUR 378.9 |
|
Description: Chlamydia trachomatis antigens from clarified cell lysate. |
|||
Neisseria Gonorrhoeae Antigen |
|||
| NG01-1000 | The Native Antigen Company | 1.0 | EUR 378.9 |
|
Description: Homogenised lysate of pure bacteria. |
|||
Mycoplasma Pneumoniae Antigen |
|||
| MP901-1000 | The Native Antigen Company | 1.0 | EUR 1010.39 |
|
Description: Mycoplasma pneumoniae whole organisms that have been purified and detergent treated to enrich antigenic proteins and decrease background. |
|||
Mycoplasma Pneumoniae Antigen |
|||
| MP901-200 | The Native Antigen Company | 0.2 | EUR 270.46 |
|
Description: Mycoplasma pneumoniae whole organisms that have been purified and detergent treated to enrich antigenic proteins and decrease background. |
|||
Echovirus Antigen, Recombinant |
|||
| REC31776-100 | The Native Antigen Company | 0.1 | EUR 276.84 |
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus |
|||
Echovirus Antigen, Recombinant |
|||
| REC31776-500 | The Native Antigen Company | 0.5 | EUR 1043.56 |
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus |
|||
Trichomonas Vaginalis Antigen |
|||
| TV01-1000 | The Native Antigen Company | 1.0 | EUR 421 |
|
Description: Washed & lysed suspension of whole protozoa |
|||
Echinococcus Granulosus Antigen |
|||
| NAT41602-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Echinococcus granulosus material is derived from bovine hydatid cyst as sterile filtered cyst fluid. |
|||
Echinococcus Granulosus Antigen |
|||
| NAT41602-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
|
Description: Echinococcus granulosus material is derived from bovine hydatid cyst as sterile filtered cyst fluid. |
|||
Enterovirus Antigen, Recombinant |
|||
| REC31772-100 | The Native Antigen Company | 0.1 | EUR 276.84 |
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus IgA, IgG and IgM ELISA. |
|||
Enterovirus Antigen, Recombinant |
|||
| REC31772-500 | The Native Antigen Company | 0.5 | EUR 1043.56 |
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus IgA, IgG and IgM ELISA. |
|||
Cytomegalovirus Purified Antigen |
|||
| CMV-HP-100 | The Native Antigen Company | 0.1 | EUR 318.94 |
|
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
|||
Cytomegalovirus Purified Antigen |
|||
| CMV-HP-1000 | The Native Antigen Company | 1.0 | EUR 2096.06 |
|
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
|||
Cytomegalovirus Purified Antigen |
|||
| CMV-HP-500 | The Native Antigen Company | 0.5 | EUR 1279.58 |
|
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
|||
Astrovirus Antigen (Type 1) |
|||
| AS02-1000 | The Native Antigen Company | 1.0 | EUR 1654.65 |
|
Description: A concentrated source of Astrovirus particles and Astrovirus proteins from a lysate of host cells. |
|||
Astrovirus Antigen (Type 1) |
|||
| AS02-200 | The Native Antigen Company | 0.2 | EUR 442.69 |
|
Description: A concentrated source of Astrovirus particles and Astrovirus proteins from a lysate of host cells. |
|||
Yersinia pestis V antigen |
|||
| REC32028-100 | The Native Antigen Company | 0.1 | EUR 491.53 |
|
Description: Yersinia pestis V antigen (LcrV antigen, capsule protein fraction 1, type III secretion system needle tip protein). The protein is produced as an N-terminal GST fusion, with GST being cleaved by thrombin and is not present in the final product. |
|||
Yersinia pestis V antigen |
|||
| REC32028-500 | The Native Antigen Company | 0.5 | EUR 2421.37 |
|
Description: Yersinia pestis V antigen (LcrV antigen, capsule protein fraction 1, type III secretion system needle tip protein). The protein is produced as an N-terminal GST fusion, with GST being cleaved by thrombin and is not present in the final product. |
|||
Canine Herpes Virus Antigen |
|||
| NAT41592-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Canine Herpes virus, produced in MDCK cells. |
|||
Canine Adenovirus 1 Antigen |
|||
| NAT41587-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Canine Adenovirus Type 1, produced in A-72 cells. |
|||
Canine Adenovirus 2 Antigen |
|||
| NAT41588-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Canine Adenovirus Type 2, produced in A-72 cells. |
|||
Canine Distemper Virus Antigen |
|||
| NAT41591-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Canine Distemper virus, produced in SL-29 cells. |
|||
Canine Parainfluenza Virus Antigen |
|||
| NAT41593-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Canine Parainfluenza virus antigen, produced in MDCK cells. |
|||
Feline Panleukopenia Virus Antigen |
|||
| NAT41597-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Feline Panleukopenia Virus (FPLV; feline parvovirus) antigen, produced in CRFK cells. |
|||
Norovirus GII.4 VP1 Antigen |
|||
| REC31620-100 | The Native Antigen Company | 0.1 | EUR 302.36 |
|
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
|||
Norovirus GII.4 VP1 Antigen |
|||
| REC31620-1000 | The Native Antigen Company | 1.0 | EUR 1830.71 |
|
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
|||
Norovirus GII.4 VP1 Antigen |
|||
| REC31620-500 | The Native Antigen Company | 0.5 | EUR 1066.53 |
|
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
|||
Cytomegalovirus Cell Lysate Antigen |
|||
| CMV-CL-100 | The Native Antigen Company | 0.1 | EUR 223.26 |
|
Description: A clarified cell lysate containing a mix of CMV antigens from all stages of the replication life cycle. |
|||
Cytomegalovirus Cell Lysate Antigen |
|||
| CMV-CL-1000 | The Native Antigen Company | 1.0 | EUR 1422.47 |
|
Description: A clarified cell lysate containing a mix of CMV antigens from all stages of the replication life cycle. |
|||
Feline Viral Rhinotracheitis Antigen |
|||
| NAT41598-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Feline Viral Rhinotracheitis (FVR; feline herpes virus, FHV-1) antigen, produced in CRFK cells. |
|||
Herpes Simplex Virus 1 Antigen |
|||
| HS105-1000 | The Native Antigen Company | 1.0 | EUR 1178.79 |
|
Description: HSV-1 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
|||
Herpes Simplex Virus 1 Antigen |
|||
| HS105-200 | The Native Antigen Company | 0.2 | EUR 294.7 |
|
Description: HSV-1 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
|||
Herpes Simplex Virus 2 Antigen |
|||
| HS205-1000 | The Native Antigen Company | 1.0 | EUR 1178.79 |
|
Description: HSV-2 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
|||
Herpes Simplex Virus 2 Antigen |
|||
| HS205-200 | The Native Antigen Company | 0.2 | EUR 294.7 |
|
Description: HSV-2 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
|||
Ross River Virus Recombinant Antigen |
|||
| REC31969-100 | The Native Antigen Company | 0.1 | EUR 757.8 |
|
Description: Recombinant Ross River virus antigen expressed in HEK293 cells as virus-like particles and purified by sucrose density gradients and precipitation. Virus-like particles were then solubilized in PBS containing 0.2% SDS to prevent aggregation of particles. The preparation is not particulate. Antigens in the preparation include Envelope proteins 1 and 2 and Nucleoprotein. |
|||
Ross River Virus Recombinant Antigen |
|||
| REC31969-500 | The Native Antigen Company | 0.5 | EUR 2844.92 |
|
Description: Recombinant Ross River virus antigen expressed in HEK293 cells as virus-like particles and purified by sucrose density gradients and precipitation. Virus-like particles were then solubilized in PBS containing 0.2% SDS to prevent aggregation of particles. The preparation is not particulate. Antigens in the preparation include Envelope proteins 1 and 2 and Nucleoprotein. |
|||
Canine Adenovirus 1 and 2 Antigen |
|||
| NAT41589-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: A mixture of Canine Adenovirus Type 1 and Type 2, produced in A-72 cells. |
|||
Hepatitis B Virus E Antigen (HBeAg) |
|||
| REC31677-100 | The Native Antigen Company | 0.1 | EUR 456.72 |
|
Description: Recombinant Hepititis B Virus E Protein (HBeAg). |
|||
Hepatitis B Virus E Antigen (HBeAg) |
|||
| REC31677-500 | The Native Antigen Company | 0.5 | EUR 1941.06 |
|
Description: Recombinant Hepititis B Virus E Protein (HBeAg). |
|||
Hepatitis B Virus Core Antigen (HBcAg) |
|||
| REC31689-100 | The Native Antigen Company | 0.1 | EUR 456.72 |
|
Description: Recombinant Hepititis B Virus Core Protein (HBcAg). |
|||
Hepatitis B Virus Core Antigen (HBcAg) |
|||
| REC31689-500 | The Native Antigen Company | 0.5 | EUR 1370.16 |
|
Description: Recombinant Hepititis B Virus Core Protein (HBcAg). |
|||
Hepatitis C Virus Core Antigen (HCcAg) |
|||
| REC31693-100 | The Native Antigen Company | 0.1 | EUR 484.79 |
|
Description: Recombinant Hepatitis C Virus core protein is produced in E. coli and fused with a His-tag. |
|||
Hepatitis C Virus Core Antigen (HCcAg) |
|||
| REC31693-500 | The Native Antigen Company | 0.5 | EUR 1455.64 |
|
Description: Recombinant Hepatitis C Virus core protein is produced in E. coli and fused with a His-tag. |
|||
Feline Infectious Peritonitis Virus Antigen |
|||
| NAT41596-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Feline Infectious Peritonitis virus (FIPV; feline coronavirus) antigen, produced in CRFK cells. |
|||
Herpes Simplex Virus 1 Lysate Antigen |
|||
| HS104-1000 | The Native Antigen Company | 1.0 | EUR 270.46 |
|
Description: A high concentration of HSV-1 particles and proteins from a clarified cell lysate. |
|||
Herpes Simplex Virus 2 Lysate Antigen |
|||
| HS204-1000 | The Native Antigen Company | 1.0 | EUR 270.46 |
|
Description: A high concentration of HSV-2 particles and proteins from a clarified cell lysate. |
|||
Legionella pneumophila antigen (native extract) |
|||
| NAT41580-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Inactivated Legionella pneumophila antigen from culture. |
|||
Streptococcus Pneumoniae Antigen, Native Extract |
|||
| NAT41604-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Inactivated Streptococcus pneumoniae antigen from culture. |
|||
Leptospira Biflexa Antigen (Strain Patoc 1) |
|||
| NAT41582-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Inactivated Leptospira biflexa antigen (Strain Patoc 1) from broth culture. |
|||
Leptospira Biflexa Antigen (Strain Patoc 1) |
|||
| NAT41582-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
|
Description: Inactivated Leptospira biflexa antigen (Strain Patoc 1) from broth culture. |
|||
Antigen 85A, 43-338aa, Mycobacterium tuberculosis, His tag, Baculovirus |
|||
| MBS204142-001mg | MyBiosource | 0.01mg | EUR 230 |
Antigen 85A, 43-338aa, Mycobacterium tuberculosis, His tag, Baculovirus |
|||
| MBS204142-005mg | MyBiosource | 0.05mg | EUR 405 |
Antigen 85A, 43-338aa, Mycobacterium tuberculosis, His tag, Baculovirus |
|||
| MBS204142-025mg | MyBiosource | 0.25mg | EUR 985 |
Antigen 85A, 43-338aa, Mycobacterium tuberculosis, His tag, Baculovirus |
|||
| MBS204142-5x025mg | MyBiosource | 5x0.25mg | EUR 4180 |
Mouse Anti-Hepatitis B Surface Antigen Antibody (1834) |
|||
| MAB12230-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus surface antigen (1834). |
|||
Mouse Anti-Hepatitis B Surface Antigen Antibody (1837) |
|||
| MAB12231-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus surface antigen (1837) |
|||
Mouse Anti-Hepatitis B Surface Antigen Antibody (1838) |
|||
| MAB12232-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus surface antigen (1838) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (1892) |
|||
| MAB12226-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1892) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (1893) |
|||
| MAB12227-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1893) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (1894) |
|||
| MAB12228-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1894) |
|||
Mycobacterium Tuberculosis major secretory protein Antigen 85A Protein |
|||
| 20-abx262511 | Abbexa |
|
|
Mycobacterium Tuberculosis major secretory protein Antigen 85A Protein |
|||
| abx262511-10mg | Abbexa | 10 mg | EUR 325 |
Mycobacterium Tuberculosis major secretory protein Antigen 85A Protein |
|||
| abx262511-25mg | Abbexa | 25 mg | EUR 6575 |
Mycobacterium Tuberculosis major secretory protein Antigen 85A Protein |
|||
| abx262511-5mg | Abbexa | 5 mg | EUR 225 |
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M132) |
|||
| MAB12298-100 | The Native Antigen Company | 0.1 | EUR 276.84 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M132) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M132) |
|||
| MAB12298-500 | The Native Antigen Company | 0.5 | EUR 695.29 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M132) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M133) |
|||
| MAB12299-100 | The Native Antigen Company | 0.1 | EUR 276.84 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M133) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M133) |
|||
| MAB12299-500 | The Native Antigen Company | 0.5 | EUR 695.29 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M133) |
|||
Mycobacterium Tuberculosis major secretory protein Antigen 85A Recombinant |
|||
| rAP-3658 | Angio Proteomie | Inquiry | Ask for price |
Recombinant Mycobacterium Tuberculosis major secretory protein Antigen 85A |
|||
| MBS144787-0002mg | MyBiosource | 0.002mg | EUR 240 |
Recombinant Mycobacterium Tuberculosis major secretory protein Antigen 85A |
|||
| MBS144787-001mg | MyBiosource | 0.01mg | EUR 310 |
Recombinant Mycobacterium Tuberculosis major secretory protein Antigen 85A |
|||
| MBS144787-1mg | MyBiosource | 1mg | EUR 5345 |
Recombinant Mycobacterium Tuberculosis major secretory protein Antigen 85A |
|||
| MBS144787-5x1mg | MyBiosource | 5x1mg | EUR 23725 |
Yersinia pestis chain B F1 capsule antigen, C-terminal His-tag |
|||
| REC32027-100 | The Native Antigen Company | 0.1 | EUR 491.53 |
|
Description: Yersinia pestis chain B F1 capsule antigen (Antig_Caf1) |
|||
Yersinia pestis chain B F1 capsule antigen, C-terminal His-tag |
|||
| REC32027-500 | The Native Antigen Company | 0.5 | EUR 2421.37 |
|
Description: Yersinia pestis chain B F1 capsule antigen (Antig_Caf1) |
|||
Ag85A Mycobacterium Tuberculosis major secretory protein Antigen 85A Recombinant Protein |
|||
| PROTP0A4V2 | BosterBio | Regular: 10ug | EUR 380.4 |
|
Description: Recombinant Mycobacterium tuberculosis Ag85A (43-338 a.a) produced in Hi-5 cells is a single, glycosylated polypeptide chain having a molecular mass of 32.8kDa (305 a.a in total).;Antigen 85A is fused to a His tag at C-terminus and purified by conventional chromatographic techniques. |
|||
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) |
|||
| MBS6006525-02mL | MyBiosource | 0.2(mL | EUR 695 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) |
|||
| MBS6006525-5x02mL | MyBiosource | 5x0.2mL | EUR 2975 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (AP) |
|||
| MBS6301005-02mL | MyBiosource | 0.2mL | EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (AP) |
|||
| MBS6301005-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (PE) |
|||
| MBS6301015-02mL | MyBiosource | 0.2mL | EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (PE) |
|||
| MBS6301015-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (APC) |
|||
| MBS6301006-02mL | MyBiosource | 0.2mL | EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (APC) |
|||
| MBS6301006-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (FITC) |
|||
| MBS6301008-02mL | MyBiosource | 0.2mL | EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (FITC) |
|||
| MBS6301008-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (Biotin) |
|||
| MBS6301007-02mL | MyBiosource | 0.2mL | EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (Biotin) |
|||
| MBS6301007-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
HCV NS3 1359-1456aa antigen |
|||
| 00154-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
|||
HCV NS3 1359-1456aa antigen |
|||
| 00154-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
|||
HLA Class 1 Antigen A25,A32 |
|||
| MBS602885-01mL | MyBiosource | 0.1mL | EUR 1290 |
HLA Class 1 Antigen A25,A32 |
|||
| MBS602885-5x01mL | MyBiosource | 5x0.1mL | EUR 5650 |
HLA Class 1 Antigen A23,A24 |
|||
| MBS602995-01mL | MyBiosource | 0.1mL | EUR 1380 |
HLA Class 1 Antigen A23,A24 |
|||
| MBS602995-5x01mL | MyBiosource | 5x0.1mL | EUR 6060 |
A549 HCP Control Antigen |
|||
| F237 | Cygnus Technologies | 50 ul | EUR 308.4 |
|
Description: A549 HCP Control Antigen by Cygnus Technologies is available in Europe via Gentaur. |
|||
Cancer Antigen 242 Antigen |
|||
| VAng-Cr3876-10kU | Creative Biolabs | 10 kU | EUR 505.2 |
|
Description: Cancer Antigen 242 Antigen, Host/Source: Metastatic Liver. The purity is detected by gel filtration. |
|||
HLA Class 1 Antigen A11 |
|||
| MBS601315-01mL | MyBiosource | 0.1mL | EUR 1380 |
HLA Class 1 Antigen A11 |
|||
| MBS601315-5x01mL | MyBiosource | 5x0.1mL | EUR 6060 |
HLA Class 1 Antigen A29 |
|||
| MBS603635-01mL | MyBiosource | 0.1mL | EUR 1380 |
HLA Class 1 Antigen A29 |
|||
| MBS603635-5x01mL | MyBiosource | 5x0.1mL | EUR 6060 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 405) |
|||
| MBS6301010-01mL | MyBiosource | 0.1mL | EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 405) |
|||
| MBS6301010-5x01mL | MyBiosource | 5x0.1mL | EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 490) |
|||
| MBS6301011-01mL | MyBiosource | 0.1mL | EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 490) |
|||
| MBS6301011-5x01mL | MyBiosource | 5x0.1mL | EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 550) |
|||
| MBS6301012-01mL | MyBiosource | 0.1mL | EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 550) |
|||
| MBS6301012-5x01mL | MyBiosource | 5x0.1mL | EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 650) |
|||
| MBS6301013-01mL | MyBiosource | 0.1mL | EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 650) |
|||
| MBS6301013-5x01mL | MyBiosource | 5x0.1mL | EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 750) |
|||
| MBS6301014-01mL | MyBiosource | 0.1mL | EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 750) |
|||
| MBS6301014-5x01mL | MyBiosource | 5x0.1mL | EUR 4250 |
Antigen 85-A Antibody (HRP) |
|||
| 20-abx109227 | Abbexa |
|
|
Antigen 85-A Antibody (FITC) |
|||
| 20-abx107809 | Abbexa |
|
|
Antigen 85-A (fbpA) Antibody |
|||
| abx110661-100l | Abbexa | 100 µl | EUR 162.5 |
A549 HCP Antigen Concentrate |
|||
| F233G | Cusabio | 200 ul | EUR 540 |
|
Description: A549 HCP Antigen Concentrate by Cygnus Technologies is available in Europe via Gentaur. |
|||
Antigen 85-A (Ag85A) Antibody |
|||
| 20-abx110661 | Abbexa |
|
|
HLA Class 1 Antigen A9,A25,A32 |
|||
| MBS603207-01mL | MyBiosource | 0.1mL | EUR 1380 |
HLA Class 1 Antigen A9,A25,A32 |
|||
| MBS603207-5x01mL | MyBiosource | 5x0.1mL | EUR 6060 |
HLA Class 1 Antigen A30,A31 (R0.92) |
|||
| MBS602833-01mL | MyBiosource | 0.1mL | EUR 1290 |
HLA Class 1 Antigen A30,A31 (R0.92) |
|||
| MBS602833-5x01mL | MyBiosource | 5x0.1mL | EUR 5650 |
Antigen 85-A Antibody (Biotin) |
|||
| 20-abx106397 | Abbexa |
|
|
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (Azide free) (HRP) |
|||
| MBS6301009-02mL | MyBiosource | 0.2mL | EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (Azide free) (HRP) |
|||
| MBS6301009-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
Here we describe strategies for the development of such fluorescent reporter M. tuberculosis strains, and their use together with confocal microscopy and movement cytometry approaches for single bacterium-level analyses of M. tuberculosis physiology and M. tuberculosis-host interactions.
